Immune cell 'Reset' could tame childhood arthritis and lupus
NCT ID NCT07490041
First seen Apr 01, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This early-phase trial is testing a new treatment called CAR-NK cells for children with rheumatic diseases like lupus and arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target and destroy faulty B cells, aiming to calm the overactive immune system. The study will enroll 36 children and focus primarily on safety, while also checking if the disease goes into remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Children's Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CD19/BCMA CAR-NK cells (KN5601)
What this could lead to
If it works, this could offer a new way to control severe pediatric rheumatic diseases by resetting the immune system without lifelong medication.
What could go wrong
This is a very early, small study (36 people) focused on safety. The treatment may not work, and there are risks like severe immune reactions or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.